Clinical Trials – Page 9 – media

This Drug Has Significant Implications for Heart Disease

An anti-inflammatory drug has significantly lowered the risk of recurrent heart attacks, strokes and cardiovascular death, all without reducing cholesterol, according to research recently published in the New England Journal of Medicine and shared at a meeting of the European Society of Cardiology.
- Source: newsjs
- 586
- August 31, 2017
anti-inflammatory cardiovascular Clinical Trials heart attacks stroke
US researchers develop anastomosis tool using medical magnets

A new anastomosis tool using a pair of medical magnets has been developed by researchers at the University of California, San Francisco, US.
- Source: medicaldevice-network
- 561
- August 28, 2017
anastomosis Clinical Trials surgical
Titan wins FDA nod to study Parkinson’s implant

Titan Pharmaceuticals’ stated today that their ropinirole implant, designed to treat the symptoms of Parkinson’s disease, was cleared by the FDA today as a new drug application.
- Source: drugdeliverybusiness
- 668
- August 25, 2017
Clinical Trials formulation implant New Approvals Parkinson
Cel-Sci raises $3.5m for head and neck cancer immunotherapy

Cel-Sci said today that for a Phase III trial of its investigational immunotherapy, it inked an agreement with institutional investors for a $3.5 million registered direct offering.
- Source: drugdeliverybusiness
- 536
- August 24, 2017
Clinical Trials Company Insight immunotherapy
Kite begins EU trial of CAR–T therapy

Kite Pharma has begun treating the first EU patients with its investigational CAR–T candidate, axicabtagene ciloleucel (axi-cel), in the safety expansion cohort of the ZUMA-1 trial.
- Source: pharmatimes
- 866
- August 10, 2017
CAR–T Clinical Trials Company Insight EU FDA
Fast-track pancreatic cancer surgery boosts success, saves money

Accelerating access to pancreatic surgery has been shown to boost success rates by more than a fifth with a cost saving to the NHS of around £3,200 per patient.
- Source: pharmatimes
- 416
- August 3, 2017
Clinical Trials NHS pancreatic
UC Riverside tests new biopsy device for cervical cancer

A research team at the University of California, Riverside (UC Riverside) in the US has evaluated a new device manufactured by tissue sampling devices maker Histologics.
- Source: medicaldevices-network.com
- 477
- August 3, 2017
cancer cervical Clinical Trials Researches
ViiV’s long-acting two-drug HIV regimen hits targets

A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence. The LATTE-2 study assessed long-acting, injectable formulations of cabotegravir (ViiV) and rilpivirine (Janssen, branded Edurant), given every four or eight weeks to patients with HIV-1 infection who had already achieved viral suppression with a daily three-drug oral regimen of cabotegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs). Following 96 weeks of maintenance treatment, viral suppression rates for the two-drug regimen dosed every eight weeks (94 percent) or every four weeks (87 percent) were comparable to the rate observed in patients continuing with a three-drug oral regimen (84 percent). In the study, data from which were published in The Lancet and presented at the annual conference ...
- Source: Medicaldevice-network
- 520
- July 27, 2017
Clinical Trials formulation HIV Researches
SLU begins trial for device to treat postpartum haemorrhage

US-based Saint Louis University (SLU) Care has started a clinical trial to evaluate the InPress Postpartum Haemorrhage Intrauterine device as a potential treatment to stop excessive bleeding for mothers after childbirth.
- Source: Medicaldevice-network.com
- 521
- July 27, 2017
Clinical Trials hemorrhage
GSK tests mepolizumab for nasal polyps

GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory disease of the nasal passage linings or sinuses causing soft tissue growth in the upper nasal cavity.
- Source: Pharmtimes
- 813
- June 28, 2017
Clinical Trials EU mepolizumab

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.